REG - Allergy Therapeutics - Satisfaction of FDI clearance conditions

Allergy TherapeuticsAnnouncement

22/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230922:nRSV2874Na&default-theme=true

RNS Number : 2874N  Allergy Therapeutics PLC  22 September 2023

 

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR
IN PART, DIRECTLY OR INDIRECTLY IN OR INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT
JURISDICTION.

THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR
OTHERWISE ACQUIRE SHARES IN ALLERGY THERAPEUTICS PLC IN ANY JURISDICTION IN
WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

THE SECURITIES DISCUSSED HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED
STATES, UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED
(THE "SECURITIES ACT"), OR PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT. NO PUBLIC OFFERING OF
THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE
INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR
SALE IN THE UNITED STATES AND THE COMPANY DOES NOT CURRENTLY INTEND TO
REGISTER ANY SECURITIES UNDER THE SECURITIES ACT. ADDITIONALLY, THE SHARES
HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND
EXCHANGE COMMISSION OR ANY OTHER SECURITIES COMMISSION OR REGULATORY AUTHORITY
IN THE UNITED STATES, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR
ENDORSED THE MERITS OF THE EQUITY FINANCING. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET
ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UNITED KINGDOM DOMESTIC
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR"). UPON
THE PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION IS NOW CONSIDERED
TO BE IN THE PUBLIC DOMAIN FOR THE PURPOSES OF MAR.

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

 

Update on Equity Financing

 

Satisfaction of FDI clearance conditions

 

22 September 2023 Allergy Therapeutics plc (AIM: AGY), the integrated
commercial biotechnology company specialising in allergy vaccines, today
confirms that all foreign direct investment (FDI) clearance conditions have
been satisfied in relation to the Equity
(https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=15740792)
Financing previously announced by the Group on 6 April 2023 (the "Equity
Financing Announcement").

 

The Equity Financing, which will raise gross proceeds of £40.75 million,
comprises (i) the Subscription (a direct subscription by each of ZQ Capital
and Southern Fox for, a minimum in aggregate, 3,385,510,000 Subscription
Shares at the Issue Price) and (ii) the Open Offer. The proceeds of the Equity
Financing will be used to repay principal amounts outstanding and accrued
interest thereon under the £40.75 million debt Facility.

 

A shareholder circular setting out the terms and conditions of the upcoming
Open Offer will be published in the next five business days (the "Circular").
A timetable for the Open Offer and completion of the Equity Financing will be
included in the Circular and the announcement of publication of the Circular.

 

The Equity Financing remains conditional on Admission of the Subscription
Shares and the Open Offer Shares to trading on AIM, and the Equity Commitment
Agreement not being terminated prior to Admission and otherwise having become
unconditional in accordance with its terms.

 

 

 

Update on Funding

The Group continues to focus on working capital and cash management to provide
time to secure additional funding following the expected interim readout of
the Phase III G306 trial in or, around, November 2023. The Group now expects
additional funding may be required during November. This requirement may be
extended into early 2024 subject to further cost control initiatives, working
capital management and timing and volume of sales in the quarter to December
2023. Discussions are continuing positively with certain significant
shareholders on providing additional funding and these discussions are
expected to result in further funding becoming available to the Group,
however, there are no binding arrangements at this stage.

Unless otherwise defined, capitalised terms shall have the meaning set out in
the Equity Financing Announcement.

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

Consilium Strategic Communications

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLBMLTMTBTBTJ